参考文献
- Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel
in pulmonary adenocarcinoma. N Eng J Med, 2009, 361(10):
947-957.[LinkOut]
- Zhou C, Wu YL, Chen G, et al. Efficacy results from the randomised
phase III OPTIMAL(CTONG 0802) study comparing first-line erlotinib
versus carboplatin(CBDCA) plus gemcitabine(GEM), in Chinese
advanced non-small-cell lung cancer (NSCLC) patients (PTS)
with EGFR activating mutations. 35th European Society for Medical
Oncology, LBA12.
- Gridelli C, Maione P, Del Gaizo F, et al. Sorafenib and sunitinib in
the treatment of advanced non-small cell lung cancer. Oncologist,
2007, 12(2): 191-200.[LinkOut]
- Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of
SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial
growth factor and platelet-derived growth factor receptors.
Clin Cancer Res, 2003, 9(1): 327-337.[LinkOut]
- Herbst RS. Imaging in drug development. Clin Adv Hematol Oncol,
2004, 2(5): 268-269.[LinkOut]
- Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad
spectrum oral antitumor activity and targets the RAF/MEK/ERK
pathway and receptor tyrosine kinases involved in tumor progression
and angiogenesis. Cancer Res, 2004, 64(19): 7099-7109.[LinkOut]
- Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical
efficacy. J Clin Oncol, 2007, 25(7): 884-896.[LinkOut]
- Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget
tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of
thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol
Metab, 2006, 91(10): 4070-4076.[LinkOut]
- Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of
oncogenic RET mutants. J Natl Cancer Inst, 2006, 98(5): 326-334.[LinkOut]
- Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available
inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic
RET kinases. Cancer Res, 2002, 62(24): 7284-7290.[LinkOut]
- Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase
inhibitor SU11248 impedes endothelial cell migrated tubule formation,
and blood vessel formation in vivo, but has little effect on existing
tumor vessels. Angiogenesis, 2004, 7(3): 225-233.[LinkOut]
- Potapova O, Laird AD, Nannini MA, et al. Contribution of individual
targets to the antitumor efficacy of the multitargeted receptor
tyrosine kinase inhibitor SU11248. Mol Cancer Ther, 2006, 5(5):
1280-1289.[LinkOut]
- Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial
of sunitinib in previously treated, advanced non-small-cell lung cancer.
J Clin Oncol, 26(4): 650-656.[LinkOut]
- Govidan V, Krzakowski M, Szczesna A, et al. Sunitinib in combination
with erlotinib for the treatment of advanced/metastatic nonsmall
cell lung cancer (NSCLC): a phase III study. 35th ESMO,
LBPL2.
- Thongprasert S, Tung Y, Kim JH, et al. Sunitinib plus erlotinib for the
treatment of advanced NSCLC: subset analysis of East Asian patients
participating in a phase III trial. 14th WCLC, MO09.02.
- Natale RB, Bodkin D, Govindan R, et al. ZD6474 versus gefitinib
in patients with advanced NSCLC: final results from a two-part,
double-blind, randomized phase II trial. J Clin Oncol, 2006, 24(18S):
Abstr7000.
- Eberhardt WE, Johnson BE, Sun Y, et al. Vandetanib plus docetaxel
versus docetaxel as second-line treatment for patients with advanced
non-small-cell lung cancer (NSCLC): a randomized, double-blind
phase III trial. Program and abstracts of the Joint 15th Congress of
the European CanCer Organisation (ECCO) and 34th Congress of
the European Society for Medical Oncology (ESMO), 2009, Abstract
O-9001.
- Vansteenkiste J, Arrieta O, Gottfried M, et al. Vandetanib plus pemetrexed
vs pemetrexed as 2nd-line therapy in patients with advanced
non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial. Program and abstracts of the Joint 15th Congress of
the European CanCer Organisation (ECCO) and 34th Congress of
the European Society for Medical Oncology (ESMO), 2009, Abstract
O-9004.
- Goss GD, Thongprasert S, Greco FA, et al. Vandetanib versus erlotinib
in patients with previously treated advanced non-small-cell
lung cancer (NSCLC): a randomized, double-blind phase III trial.
Program and abstracts of the Joint 15th Congress of the European
CanCer Organisation (ECCO) and 34th Congress of the European
Society for Medical Oncology (ESMO), 2009, Abstract O-9005.
- Ryan AJ ,Wedge SR. ZD6474 -a novel inhibitor of VEGFR and EGFR
tyrosine kinase activity. Br J Cancer, 2005, 92(Suppl 1): S6-S13.[LinkOut]
- Wilhelm S, Carter C, Lynch M, et al. Discovery and development of
sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug
Discov, 2006, 5(10): 835-844.[LinkOut]
- Scagliotti G, Von Pawel J, Reck M, et al. Sorafenib plus carboplatin/
paclitaxel in chemonaive patients with stage IIIb-IV NSCLC: Interim
analysis results from the phase III, randomized, double-blind,
placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin
and Pacltaxel Efficacy in NSCLC) trial. J Thorac Oncol, 2008, 3(suppl):
S97-S98.
- Gatzemeier U, Eisen T, Santoro A, et al. Sorafenib (S)+Gemcitabine/
Cisplatin (GC) vs GC alone in the first-line treatment of advanced
non-small cell lung cancer (NSCLC): phase III NSCLC research experience
utilizing sorafenib (NEXUS) trial. 35th EMSO, LBA16.
- Bayer. A 3rd/4th line placebo-controlled trial of sorafenib in patients
with predominantly non squamous non-small cell lung cancer
NSCLC (MISSION). NCT00863746.
- Hu-lowe DD, Zou HY, Grazzini ML, et al. Nonclinical antiangiogenesis
and antitumor activities of axitinib (AG-013736), an oral, potent,
and selective inhibitor of vascular endothelial growth factor receptor
tyrosine kinases 1, 2, 3. Clin Cancer Res, 2008, 14(22): 7272-7283.[LinkOut]
- Rini BI, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as
second-line therapy for metastatic renal cell carcinoma (mRCC): Results of phase III AXIS trial. J Clin Oncol, 2011(29): Abstr 4503.
- Schiller JH, Larson T, Qu SH, et al. Efficacy and safety of axitinib in
patients with advanced non-small-cell lung cancer: Results from a
phase II study. J Clin Oncol, 2009, 27(33): 3836-3841.[LinkOut]
- Blumenschein GR, Reckamp K, Stephenson GJ, et al. Phase Ib study
of motesanib, an oral angiogenesis inhibitor, in combination with
carboplatin/paclitaxel and/or panitumumab for the treatment fo
advanced non-small cell lung cancer. Clin Cancer Res, 2010, 16(1):
279-290.[LinkOut]
- Soda M, YL Choi, Enomoto M, et al. Identification of the transforming
EML4-ALK fusion gene in non-small-cell lung cancer. Nature,
2007, 448(7153): 561-565.[LinkOut]
- Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver
mutations in tumor specimens from 1,000 patients with lung adenocarcinoma:
The NCI’s Lung Cancer Mutation Consortium (LCMC).
ASCO, 2011: CRA7506.
- Sivachenko A, Hammerman P, Pho N, et al. Genomic characterization
and targeted therapeutics in squamous cell lung cancer. WCLC,
2011: PRS1.
- Groen HJ, Harmon CS, Williams JA, et al. Biomarker associations
with survival for refractory NSCLC patients receiving erlotinib±
sunitinib in a randomized phase 2 Trial. AACR, 2010: OA No19.
- Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous
daily sunitinib dosing in patients with previously treated advanced
non-shmall cell lung cancer. Br J Cancer, 2009, 101(9): 1543-1548.[LinkOut]
- Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously
treated non-small-cell lung cancer. N Engl J Med, 2005, 353(2):
123-132.[LinkOut]
- Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously
treated non-small-cell lung cancer (INEREST): a randomized
phase III trial. Lancet, 2008, 372(9652): 1809-1818.[LinkOut]
|